BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34019195)

  • 1. Jab1/Cops5: a promising target for cancer diagnosis and therapy.
    Yuan C; Wang D; Liu G; Pan Y
    Int J Clin Oncol; 2021 Jul; 26(7):1159-1169. PubMed ID: 34019195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging roles of Jab1/CSN5 in DNA damage response, DNA repair, and cancer.
    Pan Y; Yang H; Claret FX
    Cancer Biol Ther; 2014 Mar; 15(3):256-62. PubMed ID: 24495954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Jab1/COPS5 as a Novel Biomarker for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Human Cancer.
    Liu G; Claret FX; Zhou F; Pan Y
    Front Pharmacol; 2018; 9():135. PubMed ID: 29535627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pivotal oncogenic role of Jab1/CSN5 and its therapeutic implications in human cancer.
    Guo Z; Wang Y; Zhao Y; Shu Y; Liu Z; Zhou H; Wang H; Zhang W
    Gene; 2019 Mar; 687():219-227. PubMed ID: 30468907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging roles of Jab1/CSN5 in cancer.
    Wang L; Zheng JN; Pei DS
    Med Oncol; 2016 Aug; 33(8):90. PubMed ID: 27412572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stat3 contributes to cancer progression by regulating Jab1/Csn5 expression.
    Pan Y; Wang S; Su B; Zhou F; Zhang R; Xu T; Zhang R; Leventaki V; Drakos E; Liu W; Claret FX
    Oncogene; 2017 Feb; 36(8):1069-1079. PubMed ID: 27524414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsa-miR-24-3p increases nasopharyngeal carcinoma radiosensitivity by targeting both the 3'UTR and 5'UTR of Jab1/CSN5.
    Wang S; Pan Y; Zhang R; Xu T; Wu W; Zhang R; Wang C; Huang H; Calin CA; Yang H; Claret FX
    Oncogene; 2016 Nov; 35(47):6096-6108. PubMed ID: 27157611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSN5/JAB1 suppresses the WNT inhibitor DKK1 in colorectal cancer cells.
    Jumpertz S; Hennes T; Asare Y; Schütz AK; Bernhagen J
    Cell Signal; 2017 Jun; 34():38-46. PubMed ID: 28229932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Let-7d Inhibits Growth and Metastasis in Breast Cancer by Targeting Jab1/Cops5.
    Wei Y; Liu G; Wu B; Yuan Y; Pan Y
    Cell Physiol Biochem; 2018; 47(5):2126-2135. PubMed ID: 29975923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAB1/CSN5 and the COP9 signalosome. A complex situation.
    Chamovitz DA; Segal D
    EMBO Rep; 2001 Feb; 2(2):96-101. PubMed ID: 11258719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress.
    Zhou F; Pan Y; Wei Y; Zhang R; Bai G; Shen Q; Meng S; Le XF; Andreeff M; Claret FX
    Clin Cancer Res; 2017 Aug; 23(15):4450-4461. PubMed ID: 28270496
    [No Abstract]   [Full Text] [Related]  

  • 12. The master developmental regulator Jab1/Cops5/Csn5 is essential for proper bone growth and survival in mice.
    Samsa WE; Mamidi MK; Hausman BS; Bashur LA; Greenfield EM; Zhou G
    Bone; 2021 Feb; 143():115733. PubMed ID: 33157284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex.
    Tomoda K; Kubota Y; Arata Y; Mori S; Maeda M; Tanaka T; Yoshida M; Yoneda-Kato N; Kato JY
    J Biol Chem; 2002 Jan; 277(3):2302-10. PubMed ID: 11704659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Wang S; Oh DY; Leventaki V; Drakos E; Zhang R; Sahin AA; Resetkova E; Edgerton ME; Wu W; Claret FX
    Cancer Lett; 2019 Nov; 465():12-23. PubMed ID: 31473252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.
    Shackleford TJ; Zhang Q; Tian L; Vu TT; Korapati AL; Baumgartner AM; Le XF; Liao WS; Claret FX
    Breast Cancer Res; 2011 Jun; 13(3):R65. PubMed ID: 21689417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAB1/COPS5 is a putative oncogene that controls critical oncoproteins deregulated in prostate cancer.
    Danielpour D; Purighalla S; Wang E; Zmina PM; Sarkar A; Zhou G
    Biochem Biophys Res Commun; 2019 Oct; 518(2):374-380. PubMed ID: 31434609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. α5-nAChR contributes to epithelial-mesenchymal transition and metastasis by regulating Jab1/Csn5 signalling in lung cancer.
    Chen X; Jia Y; Zhang Y; Zhou D; Sun H; Ma X
    J Cell Mol Med; 2020 Feb; 24(4):2497-2506. PubMed ID: 31930655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of c-Jun activation domain-binding protein-1 in cancer: A systematic review and meta-analysis.
    Shi D; Mu S; Hu B; Zhang S; Liu J; Zhang Z; Shao Z
    J Cell Mol Med; 2021 Mar; 25(6):2750-2763. PubMed ID: 33550701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory mechanisms and therapeutic potential of JAB1 in neurological development and disorders.
    Yang Y; Song R; Gao Y; Yu H; Wang S
    Mol Med; 2023 Jun; 29(1):80. PubMed ID: 37365502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jab1/Cops5 contributes to chemoresistance in breast cancer by regulating Rad51.
    Liu G; Yu M; Wu B; Guo S; Huang X; Zhou F; Claret FX; Pan Y
    Cell Signal; 2019 Jan; 53():39-48. PubMed ID: 30244171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.